BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) Leading the Way as Novel Therapies Fuel Growth of Breast Cancer Treatment Market

• The market share of immunotherapy treatments for breast cancer and other malignancies is expected to increase exponentially by 2024
• The incidence of breast cancer is set to grow by 50 percent in the next decade
• BriaCell Therapeutics Corp. has already established the effectiveness of its lead candidate, Bria-IMT, in clinical trials
• A personalized, off-the-shelf immunotherapy solution, Bria-OTS, is under development

With the incidence of breast cancer expected to increase worldwide, the therapeutic market for this particular ailment is also set to grow at a CAGR of eight percent through 2023, according to industry reports (http://ibn.fm/HVYSA). Companies such as BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) will be leading the way, as the development of new treatment solutions is expected to be a primary factor contributing to the market’s growth.

According to the ‘Global Breast Cancer Therapeutics Market 2019-2023’ report, various innovative therapies are emerging to offer breast cancer patients more advanced solutions than the ones currently available. Therapies having the potential to address advanced breast cancer cases will also dominate the market in the years to come, the report concludes.

BriaCell Therapeutics Corp., an immuno-oncology focused biotechnology company, is currently testing such specialized therapies for advanced breast cancer patients. The company is developing immunotherapy solutions that have so far proven to be both highly effective and well-tolerated by patients.

Bria-IMT, the lead BriaCell cancer drug candidate, has delivered promising results in three clinical studies to date. In tests with advanced breast cancer patients, Bria-IMT contributed to tumor shrinkage. Currently, Bria-IMT’s effectiveness is being assessed in combination with KEYTRUDA (pembrolizumab) by Merck & Co., Inc. (NYSE: MRK).

Bria-IMT works by providing breast cancer antigens and stimulation of the T-cells – an important part of the immune system responsible for fighting cancer. Proof of concept for this therapy has already been achieved in clinical trials. Its safety has been established as excellent, even in the case of heavily-pretreated advanced breast cancer patients.

The combination study has treated six patients to date with Bria-IMT and KEYTRUDA. All patients tolerated the combination very well, and additional data about the efficacy of the combination will be released in the first quarter of 2019.

BriaCell Therapeutics Corp. is also working to develop Bria-OTS – a personalized, off-the-shelf immunotherapy solution for advanced breast cancer patients. Bria-OTS is expected to provide a tailor-made breast cancer solution that is much more cost-efficient and easier to manufacture than alternative treatments.

According to the company, the very same technology could be applicable to the treatment of other types of cancer.

Several studies indicate that the incidence of breast cancer is expected to increase in the next decade (http://ibn.fm/XR9CX). U.S. breast cancer diagnoses are anticipated to grow from 283,000 in 2011 to 441,000 in 2030, an increase of over 50 percent. The proportion of cases diagnosed among women in the 50-to-69 age group is expected to decrease from 55 percent to 44 percent in 2030. Diagnoses among those aged 70 to 84, however, will increase from 24 percent to 35 percent.

Immunotherapy could provide a viable solution to the problem. The cancer immunotherapy market is anticipated to grow to $145 billion by 2022, at a CAGR of 14 percent (http://ibn.fm/IBQyc). Immunotherapy currently accounts for 50 percent of the oncology medications market, but it is forecast that roughly 60 percent of previously treated cancer patients will adopt immunotherapy by 2026.

With its dedicated immunotherapies, BriaCell Therapeutics Corp. is on the front line of the battle, exploring new ways to address the unmet medical needs of advanced cancer patients. The potential market is estimated to be between $1 billion and $5 billion, depending on the stage of treatment.

For more information, visit the company’s website at www.BriaCell.com

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php